Sutezolid

Generic Name: Sutezolid

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₀FN_₃O_₃S

CAS Number: 168828-58-8

Unique Ingredient Identifier: 3A71182L8P

Background: Sutezolid has been used in trials studying the treatment of Tuberculosis.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Phase 2

Not yet recruiting

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Bedaquiline
Drug: Pyrazinamide
Drug: Pretomanid
Drug: Ethambutol
Drug: Linezolid
Drug: TBI-223
Drug: Sutezolid

First Posted Date: 2024-01-05

Last Posted Date: 2024-11-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 315

Registration Number: NCT06192160

Locations: 🇺🇬
12401, Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda
🇲🇼
30301, Blantyre CRS, Blantyre, Malawi
🇲🇼
12001, Malawi CRS, Lilongwe, Malawi

and more 21 locations

A Pan-TB Regimen Targeting Host and Microbe

Phase 2

Recruiting

Conditions: Tuberculosis

Interventions: Drug: Sutezolid
Combination Product: Rifafour
Drug: N-acetyl cysteine
Drug: Pretomanid
Drug: Bedaquiline

First Posted Date: 2023-01-17

Last Posted Date: 2024-10-07

Lead Sponsor: The Aurum Institute NPC

Target Recruit Count: 352

Registration Number: NCT05686356

Locations: 🇲🇿
Instituto Nacional de Saúde, Maputo, Mozambique
🇿🇦
Clinical HIV Research Unit, Durban, South Africa
🇿🇦
The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa

and more 4 locations

PanACEA Sutezolid Dose-finding and Combination Evaluation

Phase 2

Completed

Conditions: Other Specified Pulmonary Tuberculosis
Pulmonary Tuberculosis

Interventions: Drug: Sutezolid
Drug: Bedaquiline, Delamanid, Moxifloxacin
Drug: Midazolam oral solution

First Posted Date: 2019-05-22

Last Posted Date: 2023-05-01

Lead Sponsor: Michael Hoelscher

Target Recruit Count: 75

Registration Number: NCT03959566

Locations: 🇹🇿
Kilimanjaro Clinical Research Institute, Moshi, Arusha, Tanzania
🇹🇿
Ifakara Health Institute, Bagamoyo, Tanzania
🇹🇿
National Institute for Medical Research (NIMR - MMRC), Mbeya, Tanzania

and more 1 locations

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

Phase 1

Completed

Conditions: Tuberculosis
Tuberculosis, Pulmonary

Interventions: Drug: Sutezolid
Drug: Placebo

First Posted Date: 2017-06-26

Last Posted Date: 2018-02-08

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 32

Registration Number: NCT03199313

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy